Meril Life Sciences, a homegrown med‑tech innovator headquartered in Vapi, officially rolled out MyClip, India’s first Transcatheter Edge‑to‑Edge Repair (TEER) system for treating severe mitral regurgitation (MR) on June 14, 2025 . The debut took place during the three‑day “Structural Heart Innovation” event (June 13–15) hosted at the Meril Academy, gathering over 150 interventional cardiologists from across India along with global experts, including Prof. Ottavio Alfieri, renowned as the “Father of mitral valve repair”.
What makes MyClip a game‑changer?
Minimally invasive & accurate: In about an hour, MyClip precisely clips the mitral valve’s leaflets to prevent blood backflow, often allowing patients to go home in 3–5 days and resume light activity soon after.
Targeting high‑risk patients: Ideal for those unfit for open‑heart surgery due to age, frailty, diabetes, hypertension, obesity, or organ dysfunction.
Life‑saving outcomes backed by science: Drawing from the COAPT trial in the New England Journal of Medicine, device‑assisted TEER therapy slashed heart‑failure hospitalization by nearly half (from 67.9% to 35.8%) and mortality (from 46.1% to 29.1%) over 24 months.(1)
The Indian context: large unmet need
With only about 150 TEER procedures annually in India, mostly in younger adults aged 30–60, there's a pressing gap between need and access. Meanwhile, Meril estimates roughly 1.5 million Indians suffer from severe MR, with nearly 1.2 million cases tied to heart attack or heart failure histories.
Training, collaboration & future scale‑up
The Vapi event featured live case demos, interactive workshops, and expert-led sessions aimed at nurturing a sustainable M‑TEER ecosystem in India. By empowering clinicians with hands-on experience and skills in echocardiography, Meril plans to expand MyClip availability through public hospitals, tertiary cardiac centers, and tier 2/3 cities.(2)
What this means for patients
Reduced risk: MyClip helps mitigate the high mortality tied to untreated MR, where over half may die without intervention, and one-year mortality can hit 57%.
Better quality of life: Avoiding open‑heart surgery means quicker recovery, less pain, and faster return to daily routines.
Greater access: As training spreads and awareness grows, more patients, especially from underserved regions could benefit.
Final take: A new chapter in Indian cardiac care
Meril’s MyClip isn’t just a device, it’s a patient‑first innovation reshaping cardiac care in India. By combining advanced engineering, targeted training, and a national awareness push with MS Dhoni, Meril is building a bridge between medical possibility and patient reality. Here’s hoping this “Make‑in‑India” breakthrough paves the way for healthier hearts worldwide.
References:
Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Marx SO, Cohen DJ, Weissman NJ, Mack MJ; COAPT Investigators. “Transcatheter Mitral-Valve Repair in Patients with Heart Failure”. N Engl J Med. 2018 Dec 13;379(24):2307-2318. doi: 10.1056/NEJMoa1806640. Epub 2018 Sep 23. PMID: 30280640.
(Rh/Dr. Hansini Bhaskaran/MSM)